Schrödinger (SDGR) Competitors

Schrödinger (NASDAQ:SDGR) and Emergent BioSolutions (NYSE:EBS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, community ranking, media sentiment, profitability, valuation and dividends.

Does the MarketBeat Community believe in SDGR or EBS?

Emergent BioSolutions received 366 more outperform votes than Schrödinger when rated by MarketBeat users. Likewise, 66.77% of users gave Emergent BioSolutions an outperform vote while only 56.52% of users gave Schrödinger an outperform vote.

Company	Underperform	Outperform
Schrödinger	Outperform Votes 52 56.52%	Underperform Votes 40 43.48%
Emergent BioSolutions	Outperform Votes 418 66.77%	Underperform Votes 208 33.23%

Which has stronger valuation & earnings, SDGR or EBS?

Schrödinger has higher earnings, but lower revenue than Emergent BioSolutions. Schrödinger is trading at a lower price-to-earnings ratio than Emergent BioSolutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Schrödinger	$200.63M	6.38	$40.72M	-$1.88	-9.36
Emergent BioSolutions	$1.07B	0.45	-$760.50M	-$11.24	-0.81

Which has more volatility and risk, SDGR or EBS?

Schrödinger has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Emergent BioSolutions has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.

Do analysts prefer SDGR or EBS?

Schrödinger presently has a consensus target price of $32.60, indicating a potential upside of 85.33%. Emergent BioSolutions has a consensus target price of $12.00, indicating a potential upside of 32.60%. Given Schrödinger's stronger consensus rating and higher possible upside, research analysts plainly believe Schrödinger is more favorable than Emergent BioSolutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Schrödinger	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.82
Emergent BioSolutions	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Is SDGR or EBS more profitable?

Emergent BioSolutions has a net margin of -53.26% compared to Schrödinger's net margin of -100.42%. Emergent BioSolutions' return on equity of -34.38% beat Schrödinger's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Schrödinger	-100.42%	-38.38%	-26.66%
Emergent BioSolutions	-53.26%	-34.38%	-11.71%

Do institutionals and insiders believe in SDGR or EBS?

79.1% of Schrödinger shares are held by institutional investors. Comparatively, 78.4% of Emergent BioSolutions shares are held by institutional investors. 8.6% of Schrödinger shares are held by company insiders. Comparatively, 1.2% of Emergent BioSolutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media prefer SDGR or EBS?

In the previous week, Emergent BioSolutions had 1 more articles in the media than Schrödinger. MarketBeat recorded 4 mentions for Emergent BioSolutions and 3 mentions for Schrödinger. Schrödinger's average media sentiment score of 0.63 beat Emergent BioSolutions' score of 0.45 indicating that Schrödinger is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Schrödinger	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Emergent BioSolutions	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Schrödinger beats Emergent BioSolutions on 10 of the 19 factors compared between the two stocks.